Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

Cholesteryl ester transfer protein (CETP), required for transferring triglyceride from very-low-density lipoprotein in exchange for cholesteryl ester from high-density lipoprotein (HDL), is also involved in lipophilic antioxidant exchange. We aimed to determine the effects of the next generation potent CETP inhibitor, obicetrapib, on concentrations and plasma distributions of lipophilic antioxidants, apolipoproteins (apo), and sphingosine-1-phosphate (S1P) in an 8-week, Phase 2 trial of placebo and 2.5, 5, and 10 mg/d obicetrapib in Japanese participants (n = 12 per group). Obicetrapib robustly increased all antioxidant levels in the HDL fraction and decreased plasma levels of oxidized low-density lipoprotein.

In specific analyses of the low-dose group, obicetrapib also raised HDL2 cholesterol, apoA1, S1P, apoM, and apoE. Increased levels of monomeric-apoA1 were found in the HDL2 and HDL3 fractions and these correlated with apoM and S1P. Furthermore, we analyzed the relationship between plasma and cerebrospinal fluid (CSF) lipophilic antioxidants in a proof-of-concept study of obicetrapib 10 mg/d in early Alzheimer’s disease patients (n = 13) and demonstrated that HDL2 and CSF carotenoid and tocopherol levels were increased by obicetrapib.

These results offer a first insight into the mechanism of action for obicetrapib in terms of HDL metabolism and function, with implications for both atherogenesis and neurodegeneration. Stephane Canarelli for establishing the ultracentrifugation protocol and apolipoprotein analytic assays used in these investigations. This trial was funded by NewAmsterdam Pharma B.V., Gooimeer 2-35, 1411 DC, Naarden, The Netherlands.

Hartis Pharma SA, Nyon, Vaud, Switzerland NewAmsterdam Pharma B.V., Gooimeer 2-35, 1411 DC, Naarden, The Netherlands Marc Ditmarsch, Andrew Hsieh, Mathijs A. Kastelein Swiss Nutrition and Health Foundation, Epalinges, Vaud, Switzerland Serge Rezzi, Andrew Hodgson & Pablo Haenggi Midwest Biomedical Research, Addison, IL, USA Alzheimer Center Amsterdam, Neurologie, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands EQT Life Sciences, Amsterdam, The Netherlands Icahn School of Medicine at Mount Sinai, Mount Sinai Fuster Heart Hospital, New York, NY, USA Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC Location VUMC, Amsterdam, The Netherlands University of Colorado Anschutz Medical Campus and CPC Clinical Research, Aurora, CO, USA State University of New York Downstate School of Public Health, Brooklyn, NY, USA New Amsterdam Pharma and Hartis Pharma have applied for patents covering the use of CETP inhibitors and HDL-raising interventions for the treatment of ASCVD, Sickle Cell Disease, Alzheimer’s disease, and age-related macular degeneration. JJPK, MHD, AH, MD, and MDK are employees of NewAmsterdam Pharma and hold stocks or options.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Below is the link to the electronic supplementary material. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.